
Please try another search
Transgene SA is a biopharmaceutical company. The Company designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The Company has approximately three products in clinical development: two immunotherapy products for cancer treatment and an anti-infective immunotherapy product for chronic hepatitis B. The Company also has various other programs based on its viral vector technology in research or in pre-clinical or clinical development. The Company's activities are focused on human health and, in particular, the research and development of immunotherapy products, including therapeutic vaccines and oncolytic viruses in the field of cancer and infectious diseases. The Company's principal products include TG4010 (MVA-MUC1-IL2), Pexa-Vec (VV-TK-GM-CSF), TG6002 (VV-TK-RR-FCU1), TG1050 (Ad5-HBV) and TG4001 (MVA-HPV-IL2).
Name | Age | Since | Title |
---|---|---|---|
Alain Merieux | 85 | 2020 | Honorary Chairman |
Alessandro Riva | 62 | 2022 | CEO & Chairman of the Board |
Sandrine Flory | 53 | 2021 | Director |
Maya R. Said | 46 | 2017 | Independent Director |
Marie-Yvonne Landel-Meunier | 70 | 2017 | Independent Director |
Benoit Habert | 60 | 2000 | Director |
Pedro Romero | - | - | Member of Scientific Advisory Board |
Jean-Luc Belingard | 77 | 2013 | Non-Independent Director |
Carol Stuckley | 70 | 2023 | Independent Director |
John C. Bell | - | 2023 | Member of Scientific Advisory Board |
Michel Baguenault de Puchesse | 55 | 2024 | Director |
Emmanuelle Quiles | - | 2025 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review